Patients with acute myeloid leukemia (AML) receive unnecessarily high-dose levels of chemotherapy, according to Dr Bob Löwenberg, professor of Hematology at the Erasmus University Medical Center in Rotterdam, The Netherlands at the 16th Congress of the European Hematology Association.
Treatment with a hybridoma-derived autologous tumor immunoglobulin (Ig) idiotype (Id) vaccine extended disease-free survival (DFS) by 14 months in treatment-naive patients with advanced stage follicular lymphoma achieving complete response (CR) or CR unconfirmed (CRu) after chemotherapy, in a double-blind multicenter controlled phase 3 trial. Subgroup analysis identified that patients with the IgM heavy chain isotype and therefore an IgM-Id vaccine, had greater time to relapse than patient with the IgG isotype and IgG-Id vaccine.
Using the recommended dose of 1.3 mg/m2administered as a 3- to 5-second bolus intravenous (IV) injection on days 1, 4, 8, and 11 of 21-day cycles, patients with relapsed multiple myeloma (MM) after 1 to 3 previous lines of therapy achieved noninferior efficacy with subcutaneous versus IV delivery of the drug when receiving up to eight 21-day cycles. In addition, those in the SQ arm experienced improvement in their systemic safety profile.
CHICAGO—Among patients with chronic myeloid leukemia (CML) in the Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients (ENESTnd) study, major molecular response (MMR) rates with nilotinib remain superior to those with imatinib after follow-up extended to a median of 18.5 months.
One third of patients with newly diagnosed, advanced chronic lymphocytic leukemia (CLL) who received the combination of bendamustine and rituximab achieved a complete response, according to researchers from the German CLL Study Group.
Although thrombocytopenia is a common problem in patients with cancer, idiopathic thrombocytopenic purpura (ITP) is relatively rare and is difficult to treat when duration exceeds 6 months. ITP can be either acute (duration ≤6 months) or chronic, can occur in both adults and children, and can be primary or secondary to another disorder, including the malignancy.
Chronic myeloid leukemia (CML) is characterized by the presence of the Philadelphia chromosome (Ph), which is formed by genetic exchange between chromosomes 9 and 22 and codes for the pathogenic tyrosine kinase BCR-ABL.1-3 Historically, therapeutic interventions for CML have included busulfan, hydroxyurea, interferon-a, and stem cell transplantation.4 These therapies vary greatly in tolerability, toxicity, and efficacy.
In the first head-to-head comparison of targeted oral tyrosine kinase inhibitors as initial treatment for early-stage chronic myeloid leukemia (CML), molecular and cytogenetic remissions were more common with nilotinib compared with imatinib, the previous standard for treating early-stage CML, said Giuseppe Saglio, MD.
Results 81 - 90 of 90